Prescription Drug Sales Will Get a Boost from Increased Patient Adherence, According to the Recent Omaha Market Overview Now Available from HealthLeaders-InterStudy
February 1, 2012—Nashville, Tenn. —HealthLeaders-InterStudy, a leading provider of managed care market intelligence, reports that prescription drug sales in Omaha will see a boost from greater patient prescription adherence. Local providers are developing initiatives to improve efficiency and reduce hospital readmission.
“Prescription drug sales could get a boost as patient adherence to treatment protocols is emphasized,” said HealthLeaders-InterStudy Analyst Chris Clancy.
The outlook is also positive for pharmaceutical companies with the two academic medical centers, according to the report. These facilities have few restrictions regarding provider relationships with pharmaceutical companies. This allows pharma to have an open dialogue with providers at these medical centers, according to the report.
On the flip side, the state Medicaid program’s new co-payment requirement for both branded and generic drugs could have a negative impact on volume for some prescription drugs, according to the report.
In addition to providing detailed analysis of levers and barriers in the market, the
Omaha Market Overview answers the following questions:
- Which health systems are partnering on an Accountable Care Organization(ACO)-style initiative?
- Which health system is expanding its use of the patient-centered medical home concept?
- Which Managed Care Organizations have been in discussions with health systems about the creation of narrow network plans?
- Is there a shortage of physicians in the market?
You can view an abstract of the report
here.
Why Pharmaceutical Sales Representatives Need Market Overviews
Market Overviews provide a detailed analysis of local healthcare market drivers in 87 of the nation’s most dynamic metro areas. Market Overviews are updated throughout the year based on market events, allowing sales reps to be more nimble in their sales efforts.